IMA
ImageneBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.72
−5.98%Aug 5, 2026, 00:00 UTC
ImageneBio, Inc. reported its Q2 2026 financial results, with zero revenue, a net loss of $10.2 million, and a diluted loss per share of $0.63.
Source:
NASDAQ · Healthcare · Biotechnology · US
Aug 5, 2026, 00:00 UTC